CN102512656B - Quinapril hydrochloride medicinal composition - Google Patents
Quinapril hydrochloride medicinal composition Download PDFInfo
- Publication number
- CN102512656B CN102512656B CN201110444527XA CN201110444527A CN102512656B CN 102512656 B CN102512656 B CN 102512656B CN 201110444527X A CN201110444527X A CN 201110444527XA CN 201110444527 A CN201110444527 A CN 201110444527A CN 102512656 B CN102512656 B CN 102512656B
- Authority
- CN
- China
- Prior art keywords
- quinapril hydrochloride
- pharmaceutical composition
- lactose
- quinapril
- pregelatinized starch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- IBBLRJGOOANPTQ-JKVLGAQCSA-N quinapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 IBBLRJGOOANPTQ-JKVLGAQCSA-N 0.000 title claims abstract description 49
- 229960003042 quinapril hydrochloride Drugs 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 22
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 12
- 239000008101 lactose Substances 0.000 claims abstract description 12
- 229920000881 Modified starch Polymers 0.000 claims abstract description 11
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims abstract description 11
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims abstract description 11
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 11
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000008213 purified water Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 6
- 239000007779 soft material Substances 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 230000008901 benefit Effects 0.000 abstract description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 229960000913 crospovidone Drugs 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 3
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 2
- 102000005862 Angiotensin II Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229960002478 aldosterone Drugs 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- FLSLEGPOVLMJMN-YSSFQJQWSA-N quinaprilat Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)C(O)=O)CC1=CC=CC=C1 FLSLEGPOVLMJMN-YSSFQJQWSA-N 0.000 description 1
- 229960001007 quinaprilat Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110444527XA CN102512656B (en) | 2011-12-27 | 2011-12-27 | Quinapril hydrochloride medicinal composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110444527XA CN102512656B (en) | 2011-12-27 | 2011-12-27 | Quinapril hydrochloride medicinal composition |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102512656A CN102512656A (en) | 2012-06-27 |
CN102512656B true CN102512656B (en) | 2013-11-27 |
Family
ID=46283908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110444527XA Expired - Fee Related CN102512656B (en) | 2011-12-27 | 2011-12-27 | Quinapril hydrochloride medicinal composition |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102512656B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116981446A (en) * | 2021-03-03 | 2023-10-31 | 苏州盛迪亚生物医药有限公司 | Pharmaceutical composition containing pyridopyrimidine derivatives and preparation method thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1144598C (en) * | 1998-06-05 | 2004-04-07 | 沃尼尔·朗伯公司 | Stabilization of compositions containing ACE inhibitors using magnesium oxide |
CN1618426A (en) * | 2003-11-21 | 2005-05-25 | 上海旭东海普药业有限公司 | Medicinal composition contg. katopril, and its prepn. method |
-
2011
- 2011-12-27 CN CN201110444527XA patent/CN102512656B/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN102512656A (en) | 2012-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10016408B2 (en) | Chemokine CXCR4 receptor modulators and uses related thereto | |
TWI731354B (en) | Sodium (2r, 5s, 13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoly)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate | |
CN102249975A (en) | (S)-4-hydroxy-2-oxo-1-pyrrolidineacetamide crystal form I and preparation method and application thereof | |
CN102579440B (en) | A kind of stable levamlodipine composition | |
WO2017011517A1 (en) | Bis-amines, compositions, and uses related to cxcr4 inhibition | |
CN102008449B (en) | Lansoprazole enteric pellet and preparation method thereof | |
CN102512656B (en) | Quinapril hydrochloride medicinal composition | |
CN103690960A (en) | Lomitapide mesylate medicinal composition and preparation method thereof | |
CN102349902A (en) | Brand new drug composition containing levamlodipine besylate and candesartan cilexetil and preparation method thereof | |
MX2012011415A (en) | Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer. | |
EP3143005B1 (en) | Chemokine cxcr4 and ccr5 receptor modulators and used related thereto | |
CN103860511B (en) | A kind of Pharmaceutical composition containing Irbesartan and Amlodipine Besylate Tablet and preparation method thereof | |
AU2011270133B2 (en) | Sustained-release therapeutic agent for hypertension and renal dysfunction | |
CN106491546B (en) | A kind of preparation method of amlodipine besylate tablets | |
CN102342942A (en) | Novel oral solid medicinal composition and preparation method thereof | |
CN103127028A (en) | Capsule containing tenofovir disoproxil fumarate | |
CN102670535A (en) | Clopidogrel hydrochloride tablet | |
CN107998095A (en) | A kind of Du Lutewei film coatings tablet preparation and preparation method thereof | |
EP3429588A1 (en) | Amide-sulfamide derivatives, compositions, and uses related to cxcr4 inhibition | |
CN107550895A (en) | A kind of R-gene preparation | |
CN116354831A (en) | Separation and application of compound 1-phenyl-1, 3-propanetriamine with uric acid reducing function in coix seed | |
CN106692148A (en) | Cariprazine pharmaceutical composition and preparation method thereof | |
CN112741832A (en) | Antihypertensive pharmaceutical composition and preparation method and application thereof | |
CN101972254A (en) | Solid preparation of levamlodipine or pharmaceutically-acceptable salts thereof, and preparation method thereof | |
Fernandez-Deamo et al. | Tolerability and pharmacokinetics of repeated doses of dersalazine sodium in healthy volunteers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: YANG XIAOMAN Free format text: FORMER OWNER: TIANJIN SONGRUI MEDICAL TECHNOLOGY CO.,LTD. Effective date: 20140319 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 300250 HEDONG, TIANJIN TO: 300250 HEBEI, TIANJIN |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140319 Address after: 300250 Taixing apartment, Taixing Road, Tianjin, 14-1-102 Patentee after: Yang Xiaoman Address before: 300250 Taixing apartment, Taixing Road, Hedong District, Tianjin, 14-1-102 Patentee before: Tianjin Songrui Medical Technology Co.,Ltd. |
|
ASS | Succession or assignment of patent right |
Owner name: NANJING HAILING CHINESE MEDICINE PHARMACEUTICAL TE Free format text: FORMER OWNER: YANG XIAOMAN Effective date: 20141016 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Hao Inventor after: Sun Jingshun Inventor after: Ding Fei Inventor after: Hu Zhengfang Inventor before: Zhang Hao |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 300250 HEBEI, TIANJIN TO: 210049 NANJING, JIANGSU PROVINCE Free format text: CORRECT: INVENTOR; FROM: ZHANG HAO TO: ZHANG HAO SUN JINGSHUN DING FEI HU ZHENGFANG |
|
TR01 | Transfer of patent right |
Effective date of registration: 20141016 Address after: No. 9 Qixia Xianlin Avenue District of Nanjing City, Jiangsu province 210049 Patentee after: Nanjing Hailing Chinese Medicine Pharmaceutical Technology Research Co.,Ltd. Address before: 300250 Taixing apartment, Taixing Road, Tianjin, 14-1-102 Patentee before: Yang Xiaoman |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131127 |